Clinical Trial Update: KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for KN026 in patients with HER2-expressing gastric/gastroesophageal junction cancer; study status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• KN026

Snippet

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Conditions: Gastric/Gastroesophageal Junction Cancer | Phase 2 | Status: COMPLETED